Amyloid-beta targeting Alzheimer's candidate abandoned following Phase II
This article was originally published in Scrip
Executive Summary
AC Immune has stopped development of ACI-91 (pirenzepine) which was in a Phase II trial as an anti-amyloid-beta approach to treating Alzheimer's disease.